Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
val-mCyd · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| val-mCyd | DRUG | - |
Inclusion Criteria: * Documented clinical history of chronic hepatitis C and compensated liver disease * No antiviral treatment for hepatitis C in the 6 months prior to the Screening visit Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Patient is pregnant or breastfee...
Val-mCyd is an investigational small molecule being developed for the treatment of chronic hepatitis C. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Val-mCyd is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK on the New York Stock Exchange.
Val-mCyd is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. A Phase 1 dose escalation study has been completed.
Val-mCyd has one completed clinical trial, NCT00227435, a Phase 1 dose escalation study evaluating its safety and antiviral activity in adults with chronic hepatitis C. The study was conducted in the United States.
Val-mCyd is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial, but it remains in clinical development and has not been authorized for marketing.